131 related articles for article (PubMed ID: 32848458)
1. Erratum: Glucosamine-6-Phosphate Isomerase 1 Promotes Tumor Progression and Indicates Poor Prognosis in Hepatocellular Carcinoma [Corrigendum].
Cancer Manag Res; 2020; 12():6861-6862. PubMed ID: 32848458
[TBL] [Abstract][Full Text] [Related]
2. Erratum: Upregulation of hsa_circRNA_102958 Indicates Poor Prognosis and Promotes Ovarian Cancer Progression Through miR-1205/SH2D3A Axis [Corrigendum].
Cancer Manag Res; 2020; 12():6863. PubMed ID: 32848459
[TBL] [Abstract][Full Text] [Related]
3. Erratum: PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis: Erratum.
Du P; Luo K; Li G; Zhu J; Xiao Q; Li Y; Zhang X
Int J Med Sci; 2022; 19(3):486-487. PubMed ID: 35370468
[TBL] [Abstract][Full Text] [Related]
4. Erratum: Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma [Corrigendum].
Cancer Manag Res; 2020; 12():4169-4170. PubMed ID: 32581588
[TBL] [Abstract][Full Text] [Related]
5. Erratum: Suppressing Growth and Invasion of Human Hepatocellular Carcinoma Cells by Celecoxib Through Inhibition of Cyclooxygenase-2 [Corrigendum].
Cancer Manag Res; 2021; 13():8353-8354. PubMed ID: 34795522
[TBL] [Abstract][Full Text] [Related]
6. Erratum: Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway [Corrigendum].
Cancer Manag Res; 2021; 13():2515. PubMed ID: 33776476
[TBL] [Abstract][Full Text] [Related]
7. Glucosamine-6-Phosphate Isomerase 1 Promotes Tumor Progression and Indicates Poor Prognosis in Hepatocellular Carcinoma.
Li D; Cheng X; Zheng W; Chen J
Cancer Manag Res; 2020; 12():4923-4935. PubMed ID: 32606980
[TBL] [Abstract][Full Text] [Related]
8. Erratum: Stanniocalcin 2 (STC2) Expression Promotes Post-Radiation Survival, Migration and Invasion of Nasopharyngeal Carcinoma Cells [Corrigendum].
Cancer Manag Res; 2019; 11():10409. PubMed ID: 31853197
[TBL] [Abstract][Full Text] [Related]
9. Erratum: KLF7 Promotes Gastric Carcinogenesis Through Regulation of ANTXR1 [Corrigendum].
Cancer Manag Res; 2021; 13():6113. PubMed ID: 34377029
[TBL] [Abstract][Full Text] [Related]
10. Corrigendum: High expression of nectin-1 indicates a poor prognosis and promotes metastasis in hepatocellular carcinoma.
Wang X; Xing Z; Chen H; Yang H; Wang Q; Xing T
Front Oncol; 2023; 13():1134139. PubMed ID: 37025598
[TBL] [Abstract][Full Text] [Related]
11. Erratum: Long Noncoding RNA GAS5 Acts As A Tumor Suppressor In Laryngeal Squamous Cell Carcinoma Via miR-21 [Corrigendum].
Cancer Manag Res; 2019; 11():9047. PubMed ID: 31695496
[TBL] [Abstract][Full Text] [Related]
12. Erratum: Upregulation of Family with Sequence Similarity 83 Member D Expression Enhances Cell Proliferation and Motility via Activation of Wnt/β-Catenin Signaling and Predicts Poor Prognosis in Gastric Cancer [Corrigendum].
Cancer Manag Res; 2021; 13():3381-3383. PubMed ID: 33889026
[TBL] [Abstract][Full Text] [Related]
13. Erratum: NECTIN4 Promotes Papillary Thyroid Cancer Cell Proliferation, Migration, and Invasion and Triggers EMT by Activating AKT [Corrigendum].
Cancer Manag Res; 2019; 11():10041. PubMed ID: 31819636
[TBL] [Abstract][Full Text] [Related]
14. Erratum: IL-33 Promotes the Growth of Non-Small Cell Lung Cancer Cells Through Regulating miR-128-3p/CDIP1 Signalling Pathway [Corrigendum].
Cancer Manag Res; 2021; 13():2907. PubMed ID: 33833573
[TBL] [Abstract][Full Text] [Related]
15. Erratum: Assessment of Potential Prognostic Value of Peroxiredoxin 1 in Oral Squamous Cell Carcinoma [Corrigendum].
Cancer Manag Res; 2021; 13():7055-7056. PubMed ID: 34531683
[TBL] [Abstract][Full Text] [Related]
16. Erratum: Assessment of Potential Prognostic Value of Peroxiredoxin 1 in Oral Squamous Cell Carcinoma [Corrigendum].
Cancer Manag Res; 2021; 13():6797-6798. PubMed ID: 34512019
[TBL] [Abstract][Full Text] [Related]
17. Erratum: Long Intergenic Non-Coding RNA 01121 Promotes Breast Cancer Cell Proliferation, Migration, and Invasion via the miR-150-5p/HMGA2 Axis [Corrigendum].
Cancer Manag Res; 2022; 14():1283-1284. PubMed ID: 35378783
[TBL] [Abstract][Full Text] [Related]
18. Erratum: Comparative Study of Auto Plan and Manual Plan for Nasopharyngeal Carcinoma Intensity-Modulated Radiation Therapy [Corrigendum].
Cancer Manag Res; 2020; 12():12851. PubMed ID: 33364833
[TBL] [Abstract][Full Text] [Related]
19. Erratum: The Development of a Nomogram to Predict Post-Radiation Necrosis in Nasopharyngeal Carcinoma Patients: A Large-Scale Cohort Study [Corrigendum].
Cancer Manag Res; 2020; 12():1371. PubMed ID: 32161491
[TBL] [Abstract][Full Text] [Related]
20. Erratum: Oral Maintenance Chemotherapy Using S-1/Capecitabine in Metastatic Nasopharyngeal Carcinoma Patients After Systemic Chemotherapy: A Single-Institution Experience [Corrigendum].
Cancer Manag Res; 2020; 12():2365-2366. PubMed ID: 32308475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
